Payment overview · 2025
General Payments
$252.76
14 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Noyes Etheridge, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PINEWOOD, SC · NPI 1588007603
Verified facts
What the public records show
CMS Open Payments records show Robert Noyes Etheridge, M.D. received $252.76 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.29 | 38.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.75 | 15.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.46 | 10.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.61 | 9.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.33 | 7.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.61 | 7.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.21 | 6.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.50 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.76 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.24 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.91 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.46 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 21 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 376 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 205 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
376 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
376 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
205 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
104 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 743 | 195 |
| Jardiance | Empagliflozin | 376 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 338 | 103 |
| Losartan Potassium | Losartan Potassium | 291 | 87 |
| Metformin Hcl Er | Metformin Hcl | 285 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 89 |
| Gabapentin | Gabapentin | 262 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 247 | 89 |
| Allopurinol | Allopurinol | 233 | 48 |
| Lisinopril | Lisinopril | 208 | 51 |
| Omeprazole | Omeprazole | 207 | 48 |
| Mounjaro | Tirzepatide | 205 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 191 | 58 |
| Famotidine | Famotidine | 188 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 40 |
| Spironolactone | Spironolactone | 169 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 162 | 48 |
| Montelukast Sodium | Montelukast Sodium | 141 | 35 |
| Chlorthalidone | Chlorthalidone | 135 | 42 |
| Carvedilol | Carvedilol | 122 | 35 |
| Furosemide | Furosemide | 122 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 23 |
| Trulicity | Dulaglutide | 104 | 24 |
| Metformin Hcl | Metformin Hcl | 102 | 29 |
| Glipizide Er | Glipizide | 95 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 22 |
| Meloxicam | Meloxicam | 81 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 20 |
| Eliquis | Apixaban | 76 | 21 |
| Farxiga | Dapagliflozin Propanediol | 76 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 20 |
| Irbesartan | Irbesartan | 72 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 22 |
| Entresto | Sacubitril/Valsartan | 70 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 21 |
| Colchicine | Colchicine | 58 | 14 |
| Prednisone | Prednisone | 57 | 37 |
| Clonidine Hcl | Clonidine Hcl | 56 | 14 |
| Finasteride | Finasteride | 56 | 15 |
| Donepezil Hcl | Donepezil Hcl | 55 | 13 |
| Baclofen | Baclofen | 54 | 15 |
| Nifedipine Er | Nifedipine | 54 | 18 |
| Trazodone Hcl | Trazodone Hcl | 53 | 19 |
| Ezetimibe | Ezetimibe | 51 | 12 |
| Naproxen | Naproxen | 49 | 19 |
| Potassium Chloride | Potassium Chloride | 47 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 19 |
| Celecoxib | Celecoxib | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 16 |
| Levetiracetam | Levetiracetam | 41 | 14 |
| Tradjenta | Linagliptin | 40 | 16 |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Novolog Flexpen | Insulin Aspart | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 26 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 14 |
| Valsartan | Valsartan | 30 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 13 |
| Cilostazol | Cilostazol | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | 12 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 20 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.76 · 14 records | Lilly USA, LLC | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, MOUNJARO, PREVNAR 20, VOQUEZNA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error